In the field of plant extracts, few ingredients can simultaneously occupy the positions of "classic" and "cutting-edge" like echinacea. It's considered classic because North American Native Americans have used echinacea for centuries, and the Swiss company A.Vogel's Echinaforce product has been in continuous production for over 70 years. It's considered cutting-edge because in recent years, research on echinacea has been moving beyond its traditional "cold medicine" label, continuously expanding into new territories in immune mechanisms, skin health, and even animal health.
In 2025, the global echinacea extract market was valued at approximately US$2.435 billion, and is projected to exceed US$5.3 billion by 2035, with a compound annual growth rate of 8.11%. In China, 34% of functional tea brands have incorporated echinacea into their formulas; in Germany, 49% of herbal prescriptions contain echinacea. Behind these figures lies a "golden" ingredient for immunity that is being rediscovered.
I. CB2 Receptor: The Core Code of Echinacea's Immunomodulatory Effects
Echinacea's immunomodulatory effects do not rely on aggressive immune stimulation, but rather on a precise molecular mechanism-the binding of alkylamide compounds to the CB2 cannabinoid receptor on the surface of immune cells.
The CB2 receptor is primarily expressed on immune cells (unlike the CB1 receptor, which is mainly located in neurons). After alkylamides from echinacea bind to this receptor, they regulate the expression of cytokines such as TNF-alpha, IL-6, and IL-8 through multiple signaling pathways, including NF-κB, JNK/ATF-2, and CREB-1. The ingenuity of this mechanism lies in its "bidirectional regulatory" characteristic: it gently activates the immune system under normal conditions, while inhibiting excessive NF-κB activation during periods of inflammatory overactivation.
Furthermore, polysaccharides in echinacea can activate macrophages through the TLR4 pathway, chicoric acid and caffeic acid derivatives provide synergistic antioxidant effects, and flavonoids inhibit COX-2 (28%-85%, concentration-dependent) without affecting COX-1. This multi-component, multi-target, and bidirectional regulatory mechanism of action is the core advantage that distinguishes echinacea from synthetic immunomodulators.
II. Clinical Evidence: A "Steady" Approach to Cold Prevention
Echinacea has one of the richest clinical research histologies in the field of immunity among plant extracts.
A meta-analysis published in *Lancet Infectious Diseases* in 2007 by Shah et al., summarizing 14 randomized controlled trials, yielded two key conclusions: echinacea can reduce the risk of colds by 58% (OR 0.42, 95% CI 0.25-0.71) and shorten the average duration of colds by 1.4 days. The international authoritative nutrition database Examine.com rates the evidence level of echinacea for common cold symptoms as Grade B.
However, this is not the whole picture. Research on echinacea has always suffered from an "Achilles' heel"-poor product standardization. The dosage, formulation, extraction part (aerial parts vs. roots), and active ingredient content vary greatly among different studies, leading to inconsistent results from individual studies. Significant benefits are only shown at the meta-analysis level. This means that the efficacy of echinacea products is highly dependent on the quality of raw materials and the standardization of extraction processes.
A noteworthy trend is that high-quality, standardized products like Echinaforce have consistently demonstrated excellent performance in numerous studies. A 2012 study by Jawad et al. showed that daily administration of 0.9 mL of Echinaforce for four months significantly improved cold prevention compared to a placebo. The product's uniqueness lies in its use of hydroalcoholic extracts from the aerial parts (95%) and roots (5%) of fresh echinacea, and its strict control over endotoxin (LPS) contamination-a crucial point because studies have found that 85%-98% of the macrophage activation effect in some echinacea products may originate from bacterial endotoxin contamination, rather than the active ingredients themselves.
Choosing the right raw materials means choosing the right efficacy.
III. From Capsules to Creams: The Application Landscape of Echinacea is Expanding
If "immunity" is echinacea's main battleground, then the following three emerging directions are opening up even greater possibilities:
Direction 1: Cosmetics-A Natural Option for Sensitive Skin and Wound Care
The anti-inflammatory and antioxidant properties of echinacea extract are rapidly increasing its application in the cosmetics field. Echinacea leaf extract can inhibit COX-2 (28%-85%) without affecting COX-1, meaning it can selectively reduce inflammation without interfering with the protective function of the gastric mucosa. Its essential oil has shown significant local anti-inflammatory effects in animal studies: 48.51% inhibition of paw edema and 44.79% inhibition of ear edema.
Currently, approximately 31% of skincare brands use echinacea extract in products for sensitive skin and wound healing, and 29% of natural beauty brands incorporate it into their creams and serums. The antioxidant capacity of chicoric acid in echinacea is comparable to that of rosmarinic acid, and there is a synergistic antioxidant effect among alkylamides, caffeic acid derivatives, and polysaccharides, giving it a competitive advantage in both internal and external applications.
Direction Two: Animal Health – An Underrated Growth Potential
The application of echinacea in animal health is often overshadowed by its popularity in human health products, but the data is impressive. In pig farming, adding echinacea extract to feed can improve piglet growth performance, enhance immunity, and reduce the incidence of diarrhea. In poultry farming, echinacea extract can promote chicken growth and improve immune function. In aquaculture, it helps improve the antioxidant capacity and growth performance of aquatic organisms.
The logic behind this sector is very clear: under the global trend of reducing/banning antibiotics, the demand for plant extracts as natural immune enhancers in feed antibiotic alternatives continues to grow. Echinacea, with its mature immune-regulating mechanism and good safety record, is a natural candidate in this sector.
Direction Three: Functional Foods – From Tea Drinks to Gummies in Everyday Use
Echinacea is extending from a pharmaceutical/health supplement form "only taken when sick" to a functional food form for "daily immune maintenance." Data shows that 53% of new supplement products emphasize the immune and restorative effects of echinacea, 33% of functional beverage brands use echinacea ingredients, and 23% of health food brands have incorporated it into their product lines.
Product form innovation is particularly noteworthy. Jamieson Laboratories launched instant echinacea tablets in 2024, claiming a 43% increase in absorption rate. Functional gummies, as the fastest-growing form of supplement, have also become an important carrier of echinacea-immune gummies combining echinacea extract with ingredients such as vitamin C and zinc are becoming a popular category in the European and American markets.
IV. Global Competitive Landscape: The Position of Chinese Suppliers
In the global competitive landscape of echinacea extract, Swiss company BIOFORCE AG leads with approximately 14% market share, supported by its Echinaforce brand, which boasts a 70-year history and extensive clinical data. Among Chinese suppliers, Shaanxi Jintai Bioengineering Co., Ltd. follows closely with approximately 12% market share, with about 39% of its extract production dedicated to echinacea formulations and 46% of its products exported to North America and Europe.
It is noteworthy that China is becoming a major production and export base for echinacea raw materials. GAP-standardized planting bases, a full-chain traceability system, and international certifications such as ISO22000/EU Organic/US Organic are becoming key assets for Chinese suppliers entering the global high-end market. Xi'an Rainbow Biotechnology's organic-certified echinacea capsules, launched in 2024, claim a 41% improvement in stability, reflecting the transformation of Chinese suppliers from "raw material export" to "branding."
However, the challenges facing the industry cannot be ignored: approximately 29% of manufacturers face inconsistent extract quality, 22% of suppliers lack traceability systems, and 31% of producers report rising raw material procurement costs. In a market environment of increasing quality differentiation, suppliers with standardized planting bases and full-chain capabilities will further highlight their competitive advantages.
V. Echinacea Extract: Three Key Dimensions of Raw Material Selection
For downstream brands, the selection of echinacea extract requires attention to three easily overlooked key dimensions:
First, the selection of species and parts. The genus *Echinacea* has nine species, the most commonly used being *E. purpurea*, *E. angustifolia*, and *E. pallida*. The three species have different emphases in their efficacy: *E. purpurea* and *E. angustifolia* are interchangeable in terms of alkylamide content and have similar immunomodulatory effects; *E. pallida* has a lower alkylamide content but is rich in ketene/ketynylene structures associated with anticancer activity. The extraction site is also crucial-the aerial parts are rich in alkylamides (the core of immunomodulation), while the roots are rich in polysaccharides (macrophage activation). Different applications require customized formulations with different proportions of different parts.
Second, the selection of standardized indicators. The core active ingredients of *Echinacea purpurea* include four main categories: alkylamides, chicoric acid, echinacoside, and polysaccharides. Looking at a single indicator can be misleading-for example, while chicoric acid is a marker for *E. purpurea*, its contribution to antiviral activity is less than that of alkylamides. It is recommended to prioritize suppliers that use HPLC detection of multiple alkylamide contents as standardized indicators.
Third, endotoxin control. As mentioned earlier, bacterial endotoxin (LPS) contamination in *Echinacea purpurea* products may be the main source (85%-98%) of the macrophage-stimulating effect. High-quality echinacea extract requires strict control of endotoxin levels to ensure that its immunomodulatory effects come from active ingredients, not contaminants.
Echinacea is a "slow-burning" ingredient-it doesn't experience the overnight fame of some trendy ingredients, but thanks to solid clinical evidence, a mature supply chain, and expanding applications, it has achieved steady growth in the global immune health sector. A market size of $2.4 billion, an annual growth rate of over 8%, and diverse applications ranging from capsules and gummies to face creams and animal feed all point to one fact: the value of echinacea has not yet been fully realized.
